Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chest Pain | 22 | 2019 | 175 | 6.080 |
Why?
|
| Emergency Service, Hospital | 25 | 2019 | 431 | 4.250 |
Why?
|
| Acute Coronary Syndrome | 16 | 2019 | 175 | 3.740 |
Why?
|
| Myocardial Infarction | 16 | 2018 | 413 | 2.210 |
Why?
|
| Patient Discharge | 7 | 2019 | 169 | 1.670 |
Why?
|
| Cardiology Service, Hospital | 3 | 2015 | 22 | 1.430 |
Why?
|
| Coronary Angiography | 8 | 2018 | 136 | 1.280 |
Why?
|
| Electrocardiography | 15 | 2019 | 568 | 1.270 |
Why?
|
| Risk Assessment | 13 | 2019 | 1312 | 1.240 |
Why?
|
| Exercise Test | 5 | 2019 | 194 | 1.130 |
Why?
|
| Middle Aged | 35 | 2019 | 10868 | 1.000 |
Why?
|
| Coronary Artery Disease | 3 | 2018 | 360 | 0.910 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 1219 | 0.890 |
Why?
|
| Male | 38 | 2019 | 17872 | 0.810 |
Why?
|
| Length of Stay | 5 | 2015 | 294 | 0.800 |
Why?
|
| Female | 38 | 2019 | 18236 | 0.800 |
Why?
|
| Aged | 26 | 2019 | 9510 | 0.770 |
Why?
|
| Inpatients | 3 | 2011 | 64 | 0.760 |
Why?
|
| Decision Support Techniques | 3 | 2017 | 104 | 0.740 |
Why?
|
| Angina Pectoris | 2 | 2013 | 19 | 0.720 |
Why?
|
| Troponin | 7 | 2019 | 79 | 0.700 |
Why?
|
| Humans | 45 | 2019 | 29213 | 0.700 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 788 | 0.650 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 47 | 0.640 |
Why?
|
| Adult | 21 | 2018 | 8466 | 0.600 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.590 |
Why?
|
| Observation | 2 | 2013 | 24 | 0.580 |
Why?
|
| Anticoagulants | 4 | 2011 | 122 | 0.560 |
Why?
|
| Logistic Models | 8 | 2018 | 729 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 871 | 0.560 |
Why?
|
| Critical Pathways | 4 | 2018 | 49 | 0.560 |
Why?
|
| Emergency Medicine | 2 | 2008 | 117 | 0.530 |
Why?
|
| Retrospective Studies | 11 | 2019 | 3121 | 0.520 |
Why?
|
| Odds Ratio | 5 | 2018 | 448 | 0.470 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2008 | 82 | 0.460 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 54 | 0.450 |
Why?
|
| Emergency Treatment | 1 | 2013 | 42 | 0.450 |
Why?
|
| Heart Diseases | 2 | 2011 | 99 | 0.440 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2012 | 11 | 0.430 |
Why?
|
| Triage | 2 | 2010 | 66 | 0.430 |
Why?
|
| Coronary Vessels | 1 | 2013 | 147 | 0.410 |
Why?
|
| North Carolina | 6 | 2016 | 1424 | 0.410 |
Why?
|
| Myocardial Revascularization | 3 | 2018 | 37 | 0.410 |
Why?
|
| Hospital Costs | 1 | 2011 | 36 | 0.400 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 28 | 0.400 |
Why?
|
| Health Expenditures | 1 | 2011 | 61 | 0.400 |
Why?
|
| Patient Admission | 1 | 2011 | 53 | 0.390 |
Why?
|
| Risk Factors | 8 | 2018 | 3547 | 0.390 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 59 | 0.380 |
Why?
|
| Fibrinolytic Agents | 2 | 2008 | 70 | 0.380 |
Why?
|
| Time Factors | 7 | 2018 | 2003 | 0.370 |
Why?
|
| Prospective Studies | 9 | 2018 | 2027 | 0.370 |
Why?
|
| Registries | 7 | 2015 | 280 | 0.370 |
Why?
|
| Pulmonary Embolism | 4 | 2011 | 46 | 0.360 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 142 | 0.360 |
Why?
|
| Health Services | 1 | 2010 | 35 | 0.360 |
Why?
|
| Peptide Fragments | 2 | 2009 | 422 | 0.340 |
Why?
|
| Research Support as Topic | 1 | 2008 | 25 | 0.330 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 493 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2018 | 1694 | 0.310 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 17 | 0.310 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 726 | 0.300 |
Why?
|
| Hospitalization | 5 | 2018 | 417 | 0.300 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 864 | 0.300 |
Why?
|
| United States | 11 | 2018 | 3648 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2008 | 154 | 0.290 |
Why?
|
| Acute Disease | 7 | 2017 | 239 | 0.270 |
Why?
|
| Prognosis | 4 | 2015 | 1363 | 0.270 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 83 | 0.260 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2005 | 110 | 0.260 |
Why?
|
| Heart Failure | 5 | 2010 | 571 | 0.240 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2008 | 32 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Craniocerebral Trauma | 2 | 2015 | 56 | 0.240 |
Why?
|
| Coronary Disease | 1 | 2005 | 200 | 0.240 |
Why?
|
| Decision Making | 3 | 2016 | 180 | 0.240 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 158 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Age Factors | 4 | 2018 | 1110 | 0.210 |
Why?
|
| Comorbidity | 3 | 2009 | 546 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2013 | 3726 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2114 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2013 | 105 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 3 | 2010 | 92 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Hemorrhage | 3 | 2015 | 91 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2019 | 365 | 0.170 |
Why?
|
| Enoxaparin | 2 | 2009 | 19 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 298 | 0.170 |
Why?
|
| Heparin | 2 | 2009 | 75 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2009 | 188 | 0.160 |
Why?
|
| Troponin T | 1 | 2018 | 59 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 88 | 0.130 |
Why?
|
| Death | 1 | 2015 | 41 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 1123 | 0.130 |
Why?
|
| Algorithms | 1 | 2018 | 463 | 0.130 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 22 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 32 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2015 | 95 | 0.130 |
Why?
|
| Hypotension | 1 | 2015 | 47 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2011 | 141 | 0.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2010 | 17 | 0.120 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 18 | 0.120 |
Why?
|
| Shock | 1 | 2013 | 28 | 0.110 |
Why?
|
| Hirudins | 2 | 2009 | 19 | 0.110 |
Why?
|
| Forecasting | 2 | 2010 | 133 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2009 | 3108 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 23 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 100 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 150 | 0.100 |
Why?
|
| Coronary Care Units | 1 | 2011 | 4 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 248 | 0.100 |
Why?
|
| Models, Economic | 1 | 2011 | 18 | 0.100 |
Why?
|
| Tomography, X-Ray | 1 | 2011 | 5 | 0.100 |
Why?
|
| Cost Savings | 1 | 2011 | 32 | 0.100 |
Why?
|
| Dobutamine | 1 | 2011 | 43 | 0.100 |
Why?
|
| Drug Costs | 1 | 2011 | 42 | 0.100 |
Why?
|
| Adenosine | 1 | 2011 | 42 | 0.100 |
Why?
|
| Echocardiography | 1 | 2011 | 141 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 709 | 0.100 |
Why?
|
| Myocardium | 1 | 2011 | 170 | 0.100 |
Why?
|
| Heart | 1 | 2011 | 162 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 533 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 427 | 0.090 |
Why?
|
| Medical Audit | 1 | 2010 | 14 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2010 | 36 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 88 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 31 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 40 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 25 | 0.090 |
Why?
|
| Oxygen | 1 | 2010 | 139 | 0.090 |
Why?
|
| Information Services | 1 | 2009 | 10 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2010 | 175 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 57 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 293 | 0.080 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 15 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 29 | 0.080 |
Why?
|
| Dyspnea | 1 | 2008 | 30 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 14 | 0.080 |
Why?
|
| Tyrosine | 1 | 2008 | 22 | 0.080 |
Why?
|
| Pyridines | 1 | 2008 | 78 | 0.080 |
Why?
|
| Aspirin | 1 | 2008 | 62 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2008 | 71 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 64 | 0.080 |
Why?
|
| Patient Selection | 2 | 2008 | 257 | 0.080 |
Why?
|
| Peptides | 1 | 2008 | 118 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1365 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 55 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2007 | 111 | 0.070 |
Why?
|
| Cause of Death | 1 | 2007 | 220 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 286 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 235 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 100 | 0.070 |
Why?
|
| Sex Factors | 2 | 2005 | 632 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 196 | 0.070 |
Why?
|
| Singapore | 1 | 2005 | 10 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 795 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 42 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 375 | 0.060 |
Why?
|
| Adolescent | 4 | 2015 | 3265 | 0.060 |
Why?
|
| Injury Severity Score | 2 | 2015 | 116 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 860 | 0.060 |
Why?
|
| Prevalence | 1 | 2005 | 907 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 973 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 1168 | 0.050 |
Why?
|
| Child | 2 | 2015 | 2221 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 27 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 88 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 603 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 198 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 251 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Capnography | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 18 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 43 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 18 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 96 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 149 | 0.020 |
Why?
|
| Disease Management | 1 | 2010 | 114 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 66 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 129 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 525 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 638 | 0.020 |
Why?
|
| Cardiology | 1 | 2005 | 72 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 440 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2413 | 0.010 |
Why?
|